# Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

> **NCT05034497** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Plus Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- Leptomeningeal Metastasis

## Interventions

- **DRUG:** 186RNL

## Key facts

- **NCT ID:** NCT05034497
- **Lead sponsor:** Plus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-06
- **Primary completion:** 2025-12-21
- **Final completion:** 2026-06-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05034497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05034497, "Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05034497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*